Your browser doesn't support javascript.
loading
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
García-Barchino, Maria J; Sarasquete, Maria E; Panizo, Carlos; Morscio, Julie; Martinez, Antonio; Alcoceba, Miguel; Fresquet, Vicente; Gonzalez-Farre, Blanca; Paiva, Bruno; Young, Ken H; Robles, Eloy F; Roa, Sergio; Celay, Jon; Larrayoz, Marta; Rossi, Davide; Gaidano, Gianluca; Montes-Moreno, Santiago; Piris, Miguel A; Balanzategui, Ana; Jimenez, Cristina; Rodriguez, Idoia; Calasanz, Maria J; Larrayoz, Maria J; Segura, Victor; Garcia-Muñoz, Ricardo; Rabasa, Maria P; Yi, Shuhua; Li, Jianyong; Zhang, Mingzhi; Xu-Monette, Zijun Y; Puig-Moron, Noemi; Orfao, Alberto; Böttcher, Sebastian; Hernandez-Rivas, Jesus M; Miguel, Jesus San; Prosper, Felipe; Tousseyn, Thomas; Sagaert, Xavier; Gonzalez, Marcos; Martinez-Climent, Jose A.
Afiliação
  • García-Barchino MJ; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Sarasquete ME; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Panizo C; Department of Haematology, Clinica Universidad de Navarra, CIBERONC, University of Navarra, Pamplona, Spain.
  • Morscio J; KU Leuven, Translational Cell and Tissue Research, Department of Pathology, UZ Leuven, Leuven, Belgium.
  • Martinez A; Haematopathology Section, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
  • Alcoceba M; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Fresquet V; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Gonzalez-Farre B; Haematopathology Section, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
  • Paiva B; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Young KH; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Robles EF; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Roa S; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Celay J; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Larrayoz M; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Rossi D; Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
  • Gaidano G; Division of Haematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
  • Montes-Moreno S; Department of Pathology, Hospital Universitario and Instituto de Formacion e Investigacion Marques de Valdecilla, Santander, Spain.
  • Piris MA; Department of Pathology, Hospital Universitario and Instituto de Formacion e Investigacion Marques de Valdecilla, Santander, Spain.
  • Balanzategui A; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Jimenez C; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Rodriguez I; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Calasanz MJ; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Larrayoz MJ; Department of Genetics, School of Medicine, University of Navarra, Pamplona, Spain.
  • Segura V; Department of Genetics, School of Medicine, University of Navarra, Pamplona, Spain.
  • Garcia-Muñoz R; Bio-informatics Unit, Department of Genomics and Proteomics, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain.
  • Rabasa MP; Department of Haematology, Hospital San Pedro, Logroño, Spain.
  • Yi S; Department of Haematology, Hospital San Pedro, Logroño, Spain.
  • Li J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang M; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xu-Monette ZY; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Puig-Moron N; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Orfao A; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Böttcher S; Cancer Research Centre, Institute for Biomedical Research of Salamanca and Department of Medicine and Cytometry Service, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Hernandez-Rivas JM; Medical Clinic II, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Miguel JS; Department of Haematology, University Hospital, and Institute of Molecular and Cellular Biology of Cancer, CIBERONC, University of Salamanca, Salamanca, Spain.
  • Prosper F; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Tousseyn T; Department of Haematology, Clinica Universidad de Navarra, CIBERONC, University of Navarra, Pamplona, Spain.
  • Sagaert X; Division of Haematological Oncology, Centre for Applied Medical Research (CIMA), CIBERONC, University of Navarra, Pamplona, Spain.
  • Gonzalez M; Department of Haematology, Clinica Universidad de Navarra, CIBERONC, University of Navarra, Pamplona, Spain.
  • Martinez-Climent JA; KU Leuven, Translational Cell and Tissue Research, Department of Pathology, UZ Leuven, Leuven, Belgium.
J Pathol ; 245(1): 61-73, 2018 05.
Article em En | MEDLINE | ID: mdl-29464716
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transformação Celular Neoplásica / Herpesvirus Humano 4 / Imunossupressores Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transformação Celular Neoplásica / Herpesvirus Humano 4 / Imunossupressores Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Pathol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha